Signal
Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventative Yeztugo (lenacapavir), the first-in-class drug...
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-01-07 22:16 UTCUpdated 2026-01-07 22:16 UTC
rss
fierce_pharma
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting treatment for the viral infection.
Score total
0.89
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
All evidence
All evidence
Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventative Yeztugo (lenacapavir), the first-in-class drug had previously been...
Fierce Pharma (All) · fiercepharma.com · 2026-01-07 22:16 UTC
Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been u...
Fierce Biotech (All) · fiercebiotech.com · 2026-01-07 22:16 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Pharma (All) (1)
- Fierce Biotech (All) (1)
Top origin domains (this list)
- fiercepharma.com (1)
- fiercebiotech.com (1)